Spyre Therapeutics, Inc. (SYRE): Nasdaq/NYSE listing notice — Aeglea BioTherapeutics transfers listing to Nasdaq Capital Market to address bid price deficiency

Spyre Therapeutics, Inc.

Received notice of Minimum Bid Price non-compliance on Jan 13, 2023; initial grace period ended July 12, 2023.
Nasdaq approved transfer to Capital Market effective July 14, 2023; stock symbol remains AGLE.
Granted additional 180-day grace period until Jan 8, 2024 to regain $1.00 bid price for 10 consecutive days.
Company intends to implement reverse stock split (approved by stockholders on June 6, 2023) to regain compliance.
Failure to regain compliance by Jan 8, 2024 could result in delisting; may appeal to Nasdaq Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Spyre Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

July 13, 2023, the Company received approval from Nasdaq of the Transfer (the “Approval”). The Transfer became effective at the opening of business on July 14, 2023. The Company’s Common Stock continues to trade under the symbol “AGLE.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, but with less stringent listing requirements, although listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. In connection with the Approval, the Company has been granted an additional 180-calendar day

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-187257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.